Related Experiment Video
Updated: Aug 17, 2026

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
Published on: October 23, 2018
Renal function in surgical patients after administration of low-flow sevoflurane and amikacin
Hideyuki Higuchi1, Yushi Adachi
1Department of Anesthesia, Self Defense Force Hanshin Hospital, 4-1-50 Kushiro, Kawanishi, Hyogo 666-0024, Japan.
Purpose:
Compound A, a degradation product of sevoflurane, is nephrotoxic in rats, while aminoglycosides induce nephrotoxic injury in humans. Combining an aminoglycoside with a known nephrotoxin can enhance nephrotoxicity. We investigated the effects of aminoglycosides on renal function in surgical patients anesthetized with low-flow sevoflurane.
Methods:
We compared the urinary excretion of several biochemical markers (such as total protein, albumin, beta(2)-microglobulin, glucose, and N-acetyl-beta-glucosaminidase [NAG]) in an amikacin group ( n = 18) and a control group ( n = 19) of surgical patients anesthetized with low-flow anesthesia (1 l.min(-1)) with sevoflurane. All patients received cefotiam as an antibiotic perioperatively. In addition, the amikacin group received amikacin, an aminoglycoside, given intravenously twice a day (400 mg per day) from immediately after the induction of anesthesia to day 2 after anesthesia.
Results:
Duration of anesthesia and mean compound A concentration were 5.2 +/- 1.4 h and 27.2 +/- 8.7 ppm (mean +/- SD) in the amikacin group, and 5.1 +/- 1.7 h and 27.1 +/- 7.8 ppm in the control group respectively ( P > 0.05). The two groups did not differ in clinical laboratory baseline values (blood urea nitrogen and serum creatinine concentration). There were no significant differences between the groups in either the maximum or the average values for the urinary excretion of biochemical markers after anesthesia.
Conclusion:
Our study demonstrates that there is no synergic effect of compound A and amikacin on nephrotoxicity in humans.
Insights
This study found no increased kidney damage when amikacin was given with sevoflurane anesthesia. Combining an aminoglycoside antibiotic with sevoflurane did not worsen nephrotoxicity in surgical patients.
Area of Science:
- Anesthesiology
- Nephrology
- Pharmacology
Background:
- Compound A, a sevoflurane degradation product, is nephrotoxic in rats.
- Aminoglycosides are known to cause nephrotoxic injury in humans.
- Concurrent administration of nephrotoxins may potentiate renal damage.
Purpose of the Study:
- To investigate the potential synergistic nephrotoxic effects of aminoglycosides in patients undergoing anesthesia with low-flow sevoflurane.
- To assess the impact of amikacin on renal function markers during sevoflurane anesthesia.
Main Methods:
- A comparative study involving 18 patients receiving amikacin and 19 control patients.
- Both groups received sevoflurane anesthesia with low fresh gas flow (1 L/min) and cefotiam antibiotic.
- Urinary excretion of biomarkers including total protein, albumin, beta(2)-microglobulin, glucose, and NAG was measured.
- Amikacin was administered intravenously at 400 mg/day from anesthesia induction to day 2 post-anesthesia.
Main Results:
- Anesthesia duration and mean Compound A concentrations were similar between the amikacin and control groups (P > 0.05).
- Baseline renal function markers (blood urea nitrogen, serum creatinine) showed no significant differences between groups.
- No significant differences were observed in the maximum or average urinary excretion of measured biochemical markers post-anesthesia.
Conclusions:
- The co-administration of amikacin and sevoflurane did not result in a synergistic increase in nephrotoxicity in human surgical patients.
- This study suggests that amikacin does not potentiate Compound A-induced nephrotoxicity under these clinical conditions.
More Related Videos
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
03:02Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification
Published on: July 25, 2025
Related Concept Videos
Stages of General Anesthesia
Parenteral Anesthetics: Overview
Inhalational Anesthetics: Overview
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Imaging Studies VII: Vascular Imaging
Acute Kidney Injury IV: Diagnostic Studies and Prevention